Evogene (NASDAQ:EVGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note published on Tuesday. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Down 4.5 %

Shares of EVGN stock opened at $0.61 on Tuesday. The company has a market capitalization of $25.22 million, a PE ratio of -1.15 and a beta of 1.49. The firm has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $0.73. Evogene has a twelve month low of $0.45 and a twelve month high of $1.44.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.73 million. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. During the same period in the prior year, the company posted ($0.07) earnings per share.

Hedge Funds Weigh In On Evogene

A number of institutional investors and hedge funds have recently bought and sold shares of EVGN. Silverarc Capital Management LLC boosted its position in shares of Evogene by 3,000.0% during the 3rd quarter. Silverarc Capital Management LLC now owns 3,100,000 shares of the biotechnology company’s stock valued at $1,818,000 after purchasing an additional 3,000,000 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Evogene during the 3rd quarter valued at about $303,000. Renaissance Technologies LLC boosted its position in shares of Evogene by 51.8% during the 1st quarter. Renaissance Technologies LLC now owns 459,081 shares of the biotechnology company’s stock valued at $597,000 after purchasing an additional 156,716 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Evogene by 49.7% during the 1st quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock valued at $265,000 after purchasing an additional 67,867 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Evogene during the 1st quarter valued at about $48,000. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.